On June 22, 2021 vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") reported that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts) (Press release, vTv Therapeutics, JUN 22, 2021, View Source [SID1234584235]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stephen Marcus, M.D., president and chief executive officer of Cantex, stated: "RAGE has been implicated in several serious cancer complications associated with increased mortality and decreased quality of life. Our team has deep expertise and a successful track record in transforming known drugs into innovative products with large clinical and commercial potential. As such, the opportunity to develop azeliragon, a phase 2-ready oral medication administered once daily, which has demonstrated a good safety profile in several Alzheimer’s disease trials, is an excellent fit for Cantex. We intend to move rapidly to prepare for clinical trials assessing the potential of azeliragon for the treatment of a number of complications associated with cancer."

"RAGE is a highly attractive target for the treatment of a wide spectrum of disorders," said Steve Holcombe, president and chief executive officer of vTv. "We believe Cantex is the right partner to further the development of azeliragon, which vTv had studied in Alzheimer’s disease, in new therapeutic indications. They have deep experience in clinical development and the proven capability of repurposing drug candidates for new indications."

Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon and the companies will allocate downstream profits under a tiered arrangement.

About Azeliragon
Azeliragon, also known as TTP488, is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). vTv Therapeutics discovered azeliragon using its proprietary drug discovery platform, TTP Translational Technology, and developed it into phase 3. A broad range of evidence suggests that RAGE—ligand interactions lead to sustained inflammatory states that play a role in chronic diseases.